Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Vaccine hesitancy grows ahead of Thailand's mass inoculation rollout

Published 05/25/2021, 04:38 AM
Updated 05/25/2021, 04:40 AM
© Reuters. A person receives China's Sinovac coronavirus disease (COVID-19) vaccine at the Central Vaccination Center, inside the Bang Sue Grand Station, in Bangkok, Thailand, May 24, 2021. REUTERS/Athit Perawongmetha

By Chayut Setboonsarng

BANGKOK (Reuters) - Vaccine hesitancy has risen sharply in Thailand opinion polls show, just weeks away from the start of a mass inoculation programme and as the country fights its deadliest COVID-19 outbreak.

Reasons for the rise in vaccine hesitancy were unclear in the polls, but there are widespread complaints at government disorganisation, delays in getting vaccines and reliance on Sinovac and locally made AstraZeneca (NASDAQ:AZN) doses.

Thailand has reported 135,439 infections and 832 deaths since the pandemic began last year.

In January, 83% of Thais surveyed by polling firm YouGov were willing to be vaccinated, but by May that dropped to 63% in the same poll, lower than Vietnam and the Philippines at 83% and 66% willingness, respectively.

Thai-based Suan Dusit Poll on Sunday echoed the YouGov findings of rising vaccine hesitancy, with 64% of respondents willing to be vaccinated, compared with 66% in January.

Dissatisfaction with the military-backed government's vaccine strategy has been building for months.

"People are worried about the vaccines that the government procured. It's not that we don't want to get shots, but there is hesitancy," Facebook (NASDAQ:FB) user Than Tongkum wrote under a government announcement encouraging vaccinations.

Asked by Suan Dusit poll for their views on Thai vaccinations, only 57% of respondents believed they would help develop immunity and reduce the virus impact, while 59% worried about side-effects.

With Thailand's main vaccination drive, which is due to start June 7, relying heavily on AstraZeneca, respondents had 66% confidence in the shot, fourth behind U.S.-developed vaccines, with Pfizer (NYSE:PFE) top at 75%.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Thailand aims to inoculate 70% of its population by year-end, a level its tourist hotspots must also reach locally before reopening to vaccinated foreign visitors.

Registration is ongoing for the first 16 million people including those over 60 or with health conditions.

So far, 7.8 million people have registered.

Government spokesman Anucha Burapachaisri said he believes the vaccines will be embraced once the inoculation programme starts.

"As Thailand receives more doses, there will be more vaccine sites, which will help create awareness among the public after they see large numbers of vaccinations do not lead to serious side effects," he told Reuters.

Actress Araya "Chompoo" Hargate sparked controversy after she posted to her 10.5 million followers on Instagram saying she chose Sinovac.

"Can't help but think this is government PR," wrote user iloveurdadmaybe.

Among the concerns is perception that Sinovac has a low efficacy rate.

"Just hearing that it's Sinovac that's only 50% safe and 50% effective," wrote Facebook user Dang Juntawan.

"Injections are on chance. If you're unlucky you'll die."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.